Wim, I agree. The numbers, for whatever reason are way off. The one thing I noticed was the very small over all sales based on script numbers. That is I think is the most important number for us to gauge Seroquel.
if you take just the last report of Seroquel you are lead to think that 1 prescription costs $677. That actually is reasonable. I take numerous meds and a 3 month supply runs from the low of $400 to a high of $1600. Then we have no idea if they are scripts for 90 day supply or just a 30 day supply.
what you then have to take into account is that $677 for each script is retail price. once you take off costs of distribution, cost of advertising, costs for packaging,price adjustments for medicare reimbursement, possible company pricing coupons, overhead, manufacturing etc. by the time you get to the end, just what is the profit that ends up getting spilt? maybe $50 dollars on each script? even say $100. if the company is reporting only 726 scripts that is only 76,000 dollars profit for that week. NOT the actual sales.
So I think one way to gauge is to look at the overall prescriptions under MNK and that those numbers go up. so until then, I agree we may only see 1.5 million in revenue for 4QE17. This would also explain the company pushing back their forecast of CFP until 2QE18. They know that for now these contracts are locked out and they need to wait to reenter and bid.
